16 December 2025
Full Year Results for the year ended 30 September 2025 Resilient FY25 performance with £2bn of future pipeline opportunities The Group announces its annual…
GOODWIN PLC CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS for the half year ended 31st October 2025 CHAIRMAN’S STATEMENT The Board reports a solid trading performance…
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps · First and only ultra-long-acting biologic with…
16 December 2025 Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus Convenient subcutaneous option has potential to reach…
16 December 2025 Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive…
15 December 2025
15 December 2025 B.P. Marsh & Partners Plc (“B.P. Marsh”, “the Company” or “the Group”) Special Dividend Declaration Further to the announcement made on…
11 December 2025
Hargreaves Services plc (“Hargreaves”, the “Company” or the “Group”) Trading Update and Notice of Interim Results Hargreaves Services plc (AIM: HSP), a diversified group delivering services…
10 December 2025
10 December 2025 Dotdigital Group plc (“Dotdigital” or the “Group”) Share Buyback Programme Dotdigital Group plc (AIM: DOTD), the leading SaaS provider of an all-in-one customer experience…